Q2 2025 Collegium Pharmaceutical Inc Earnings Call Transcript
Key Points
- Collegium Pharmaceutical Inc (COLL) reported a 29% year-over-year increase in revenue for the second quarter of 2025, driven by strong performance across its portfolio.
- Jornay PM, a key growth driver, achieved a 23% year-over-year increase in prescriptions and generated record quarterly revenues of $32.6 million.
- The company completed a $25 million accelerated share repurchase program and announced a new $150 million share repurchase program authorized through December 2026.
- Collegium Pharmaceutical Inc (COLL) raised its 2025 financial guidance, expecting total revenue growth of approximately 19% year-over-year.
- The company generated $72.4 million in cash from operations, increasing its cash position to $222 million while paying down $16.1 million of debt.
- Operating expenses increased significantly, with GAAP operating expenses up 69% year-over-year and non-GAAP adjusted operating expenses up 104% year-over-year.
- GAAP net income decreased to $12 million from $19.6 million in the second quarter of 2024.
- The company faces challenges in raising awareness and adoption of Jornay PM among healthcare providers and patients, particularly in the adult ADHD market.
- Despite strong performance, the company remains cautious about revisiting the $300 million to $400 million peak sales estimate for Jornay PM.
- There is ongoing uncertainty regarding potential generic competition for its pain portfolio, although no immediate threats are identified.
Greetings, and welcome to the Collegium Pharmaceuticals second quarter 2025 earnings conference call. (Operator Instructions) Please note, this conference is being recorded.
I'll now turn the conference over to Ian Karp, Head of Investor Relations at Collegium. Thank you. You may now begin your presentation.
Great. Thanks, and welcome to Collegium Pharmaceuticals Second Quarter 2025 Earnings Conference Call. I'm joined today by Vikram Karnani, our President and Chief Executive Officer; Colleen Tupper, our Chief Financial Officer; and Scott Dreyer, our Chief Commercial Officer.
Before we begin today's call, we want to remind participants that none of the information presented today is intended to be promotional and that any forward-looking statements made today are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
You are cautioned that such forward-looking statements involve risks and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
